PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31225433-6	2017	Clonogenicity and proliferation assays showed that H19 overexpression could suppress tumor cell survival and proliferation after treatment with either sorafenib or doxorubicin, suggesting chemosensitizing actions of H19.	Doxorubicin	164-175	H19 imprinted maternally expressed transcript	Homo sapiens	51-54	
31225433-10	2017	Chemoresistant cells were sensitized after H19 overexpression by either increasing the cytotoxic action of doxorubicin or decreasing cell proliferation upon sorafenib treatment.	Doxorubicin	107-118	H19 imprinted maternally expressed transcript	Homo sapiens	43-46